1 day Ago By ABMN Staff
Renaissance Technologies LLC trimmed its holdings in shares of Precigen, Inc. ( NASDAQ:PGEN – Free Report ) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 1,067,645 shares of the biotechnology company’s stock after selling 532,545 shares during the period. Renaissance Technologies LLC’s holdings in Precigen were worth $1,196,000 as of its most recent SEC filing. Several other institutional investors have also recently modified their holdings of the stock.
Envestnet Asset Management Inc. grew its holdings in Precigen by 29.0% during the 4th quarter.
Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 5,915 shares during the last quarter. Invesco Ltd.
boosted its stake in shares of Precigen by 14.6% during the fourth quarter. Invesco Ltd.
now owns 47,307 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 6,040 shares during the last quarter. Stoneridge Investment Partners LLC increased its position in Precigen by 21.3% during the 4th quarter.
Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 12,063 shares in the last quarter. Wells Fargo & Company MN raised its stake in Precigen by 12.0% in the 4th quarter.
Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 12,285 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Precigen by 27.9% in the 4th quarter.
SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 12,578 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades A number of research firms have recently weighed in on PGEN. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Precigen in a research report on Thursday, March 20th.
JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company.
According to MarketBeat.com, Precigen currently has a consensus rating of “Moderate Buy” and an average target price of $7.00.
Precigen Stock Down 0.6 % PGEN stock opened at $1.54 on Wednesday.
Precigen, Inc. has a 52 week low of $0.65 and a 52 week high of $2.
17. The company has a market cap of $452.83 million, a price-to-earnings ratio of -2.
80 and a beta of 1.70. The business has a fifty day simple moving average of $1.
59 and a 200-day simple moving average of $1.25. Precigen ( NASDAQ:PGEN – Get Free Report ) last released its quarterly earnings data on Wednesday, March 19th.
The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.
02. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.
30 million. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.
68%. As a group, analysts expect that Precigen, Inc. will post -0.
32 earnings per share for the current fiscal year. Precigen Profile ( Free Report ) Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
See Also Want to see what other hedge funds are holding PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. ( NASDAQ:PGEN – Free Report ).
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter ..
